TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06826196: A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

Sponsor: Aldena Therapeutics · Phase: PHASE1/PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 24 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$723,690

Rescue Site Savings

+$482,460

Unlock Full NCT06826196 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06826196 Rescue Dossier →